Industry Symposium 10 【Astellas】

16 Aug 2025 13:30 15:00
TICC - 1F 101C
Recent Advancements in Muscle-Invasive Urothelial Carcinoma

Recent advancements in the management of muscle-invasive urothelial carcinoma (MIUC) have centered on integrating immunotherapy and targeted approaches. Immune checkpoint inhibitors, such as PD-1/PD-L1 blockers, have become important in both neoadjuvant and adjuvant settings, especially for cisplatin-ineligible patients.

 

A key innovation is the use of antibody-drug conjugates (ADCs), notably enfortumab vedotin, which targets Nectin-4. When combined with checkpoint inhibitors like pembrolizumab, this approach has shown synergistic anti-tumor activity in advanced urothelial carcinoma. Ongoing trials are now exploring these combinations in earlier stages, including the neoadjuvant setting for MIUC.

 

These developments, alongside advances in molecular profiling and biomarker-guided therapy, are redefining treatment paradigms—offering new hope for improved outcomes and potential bladder preservation in selected patients.

Time Session
13:30
13:40
13:40
14:20
Cheng-Kuang YangTaiwan Speaker Robotic Radical Prostatectomy: Trying to Fit the Right Surgery to the Right PatientDefinitive treatment for localized prostate cancer included radical prostatectomy and radiation. Successful criteria of radical prostatectomy have to meet oncology control, not persistent PSA after surgery without salvage therapy. MRI imaging stage and PSA density are predictors for short‐term BCR after prostatectomy. NCCN‐defined high‐risk patients with a high initial PSA 28 density, imaging stage (T3aN0M0 and T3bN0M0), and 29 pathologic stage (any N1) had a higher risk of BCR when 30 compared with other patients with undetectable PSA, while 31 those with pathologic stage (T3bN0M0 or any N1) displayed 32 a higher risk of postoperatively detectable PSA. These find‐ 33 ings may help urologists to identify patients for whom active 34 therapeutic protocols are necessary.
14:20
14:55
Cheng-Kuang YangTaiwan Speaker Robotic Radical Prostatectomy: Trying to Fit the Right Surgery to the Right PatientDefinitive treatment for localized prostate cancer included radical prostatectomy and radiation. Successful criteria of radical prostatectomy have to meet oncology control, not persistent PSA after surgery without salvage therapy. MRI imaging stage and PSA density are predictors for short‐term BCR after prostatectomy. NCCN‐defined high‐risk patients with a high initial PSA 28 density, imaging stage (T3aN0M0 and T3bN0M0), and 29 pathologic stage (any N1) had a higher risk of BCR when 30 compared with other patients with undetectable PSA, while 31 those with pathologic stage (T3bN0M0 or any N1) displayed 32 a higher risk of postoperatively detectable PSA. These find‐ 33 ings may help urologists to identify patients for whom active 34 therapeutic protocols are necessary.
14:55
15:00